USMLE Step 1 & 2 Pharmacokinetics (ADME)
Last updated: May 2, 2026
Pharmacokinetics (ADME) questions are one of the highest-leverage areas to study for the USMLE Step 1 & 2. This guide breaks down the rule, the elements you need to recognize, the named traps that catch most students, and a memory aid that scales to test day. Read it once, then practice the same sub-topic adaptively in the app.
The rule
Pharmacokinetics (PK) describes what the body does to a drug across four phases — Absorption, Distribution, Metabolism, Excretion. Three derived parameters do most of the USMLE work: volume of distribution ($V_d$) determines the loading dose, clearance (CL) determines the maintenance dose and steady-state concentration, and half-life ($t_{1/2}$) determines how long until steady state and how long until washout. Most stems test whether you can pick the right equation for the question being asked rather than memorize numbers.
Elements breakdown
Absorption
Movement of drug from the site of administration into systemic circulation; quantified by bioavailability (F).
- IV: F = 1 by definition
- Oral: F reduced by first-pass hepatic metabolism
- Weak acids absorbed in acidic stomach (nonionized)
- Weak bases absorbed in alkaline small bowel
- Ion trapping reverses in urine for excretion
Distribution
Drug movement from blood into tissues, quantified by volume of distribution: $V_d = \frac{\text{dose}}{C_0}$.
- Low $V_d$ (<10 L): plasma-bound, large/charged
- Medium $V_d$ (10–40 L): extracellular fluid
- High $V_d$ (>40 L): tissue-bound, lipophilic
- Increased in burns, sepsis, pregnancy
- Decreased in dehydration
Common examples:
- Heparin, warfarin (low)
- Aminoglycosides (medium)
- Chloroquine, TCAs, digoxin (high)
Metabolism
Biotransformation, primarily hepatic, into more polar (excretable) metabolites.
- Phase I: oxidation/reduction/hydrolysis (CYP450)
- Phase II: conjugation (glucuronidation, sulfation, acetylation)
- Inducers: chronic alcohol, phenytoin, phenobarbital, rifampin, griseofulvin, carbamazepine, St. John's wort
- Inhibitors: acute alcohol, sulfonamides, isoniazid, cimetidine, ketoconazole, erythromycin, grapefruit juice
- Slow acetylators: INH, hydralazine, procainamide, dapsone (lupus, neuropathy risk)
Excretion
Elimination of drug or metabolite, primarily renal; quantified by clearance: $\text{CL} = \frac{0.7 \times V_d}{t_{1/2}}$.
- Filtered: free, unbound, water-soluble
- Secreted: organic acids/bases (penicillin, probenecid)
- Reabsorbed: lipophilic, nonionized
- Weak acid OD → alkalinize urine (bicarb for aspirin)
- Weak base OD → acidify urine (rarely done clinically)
Kinetic order
Whether elimination rate depends on concentration.
- First-order: constant fraction eliminated/unit time
- Zero-order: constant amount eliminated/unit time
- Zero-order drugs: Phenytoin, Ethanol, Aspirin (high dose) — "PEA"
Steady state and dosing
Steady state reached in 4–5 half-lives regardless of dosing interval.
- Loading dose $= \frac{C_p \times V_d}{F}$
- Maintenance dose $= \frac{C_p \times \text{CL} \times \tau}{F}$
- Loading dose unchanged in renal/hepatic failure
- Maintenance dose decreased in renal/hepatic failure
Common patterns and traps
The Loading-Dose-Unchanged Trap
The stem describes a patient with renal or hepatic failure starting a new drug and asks about the loading dose. The wrong answer reduces the loading dose proportionally to creatinine clearance or Child-Pugh class. The correct answer keeps loading unchanged and reduces only the maintenance dose. The principle: loading dose fills the volume of distribution, which is unaffected by elimination organ function (acutely).
A choice that says 'reduce loading dose by 50% because of renal failure' or 'give half the calculated loading dose because of cirrhosis' — both wrong.
The Zero-Order PEA Pattern
The stem shows a patient with a drug whose plasma level rises disproportionately to a small dose increase, or a toxic ingestion where elimination time does not shorten with hemodialysis prediction by half-life. The drug is almost always Phenytoin, Ethanol, or Aspirin (at toxic doses). The trap is treating these like first-order drugs and predicting that doubling the dose doubles the level — instead, doubling the dose may quadruple it once enzymes saturate.
A choice claiming 'first-order elimination' for a phenytoin patient whose level jumped from 15 to 35 mg/L after a small dose increase — the answer is zero-order (Michaelis-Menten saturation).
The CYP Inducer/Inhibitor Drug-Drug Interaction
The stem layers a chronic medication on top of warfarin, an OCP, cyclosporine, or another narrow-therapeutic-index drug, then asks why INR jumped or why the patient got pregnant. The trap is picking pharmacodynamic synergy when the answer is CYP450 induction or inhibition. Recognize the inducer/inhibitor list cold; the stem will not name 'CYP3A4' explicitly.
A patient on warfarin started on rifampin develops a subtherapeutic INR — the answer is hepatic enzyme induction increasing warfarin metabolism, not 'decreased absorption' or 'protein binding displacement.'
The Ion-Trapping/Urine-Alkalinization Setup
A toxic ingestion stem (most often aspirin, sometimes phenobarbital or methotrexate) asks for an intervention that accelerates renal elimination. The correct answer is sodium bicarbonate to alkalinize the urine, which ionizes the weak acid in the tubule and prevents reabsorption. Distractors offer activated charcoal (only useful early), hemodialysis (correct only in severe toxicity), or acidification (wrong direction).
The Bioavailability/First-Pass Switch
A patient stable on IV morphine, lidocaine, propranolol, or nitroglycerin is being transitioned to oral. The stem asks why the oral dose is much higher than the IV dose. The answer is extensive first-pass hepatic metabolism reducing oral bioavailability. The trap is picking 'poor absorption' or 'protein binding' when the issue is presystemic hepatic extraction.
How it works
Anchor every PK question on which parameter is being asked about. If the stem asks how much drug to give right now to hit a target plasma level, you need $V_d$ — that's a loading-dose question. If the stem asks how much to give per hour or per day to keep a target level, you need clearance — that's a maintenance question. If the stem gives you a dose and a measured trough or peak and asks for $V_d$, rearrange $V_d = \text{dose}/C_0$. Consider Mr. Reyes, started on IV gentamicin: the renal team wants a peak of 8 mg/L, $V_d$ is 0.25 L/kg, and he weighs 80 kg — loading dose is $8 \times (0.25 \times 80) = 160$ mg, and renal failure does not change that number because $V_d$ does not depend on kidney function. The maintenance dose, however, must be cut because clearance falls. Recognize that pattern and the math is mechanical.
Worked examples
Which of the following is the most appropriate adjustment for the loading dose of tobramycin in this patient?
- A Give the full calculated loading dose of approximately 140 mg, unchanged for renal function ✓ Correct
- B Reduce the loading dose to 35 mg (75% reduction) to match the reduction in creatinine clearance
- C Omit the loading dose entirely and use only adjusted maintenance dosing
- D Reduce the loading dose by 50% and extend the dosing interval to every 48 hours
Why A is correct: Loading dose depends only on the target plasma concentration and the volume of distribution: $\text{loading dose} = C_p \times V_d = 8 \text{ mg/L} \times (0.25 \text{ L/kg} \times 70 \text{ kg}) = 140 \text{ mg}$. Volume of distribution is not altered acutely by renal failure, so the loading dose is unchanged. Only the maintenance dose (or interval) needs adjustment because clearance is reduced.
Why each wrong choice fails:
- B: This conflates clearance with volume of distribution. Reducing the loading dose proportionally to creatinine clearance is the classic trap — it would leave the patient subtherapeutic during the critical first hours of bacteremia treatment. (The Loading-Dose-Unchanged Trap)
- C: Omitting the loading dose delays achieving therapeutic concentration to 4–5 half-lives, which is dangerously slow in gram-negative sepsis. Loading is independent of elimination function. (The Loading-Dose-Unchanged Trap)
- D: Extending the maintenance interval to every 48 hours is reasonable for the maintenance phase, but the loading-dose reduction is wrong for the same reason as choice B — $V_d$ does not change with renal function. (The Loading-Dose-Unchanged Trap)
Which property of phenytoin elimination best explains this disproportionate rise in serum concentration?
- A First-order kinetics with a constant elimination half-life
- B Saturation of metabolizing enzymes producing zero-order kinetics ✓ Correct
- C Induction of cytochrome P450 enzymes by chronic dosing
- D Increased volume of distribution at higher plasma concentrations
Why B is correct: Phenytoin follows Michaelis-Menten (zero-order) kinetics within the therapeutic range because hepatic metabolizing enzymes saturate at clinically relevant concentrations. Once saturated, a constant amount — not a constant fraction — is eliminated per unit time, so a small dose increase produces a disproportionately large rise in plasma level. Phenytoin, ethanol, and high-dose aspirin all exhibit this PEA pattern.
Why each wrong choice fails:
- A: First-order kinetics would predict a roughly proportional rise (33% dose increase → 33% concentration increase, to about 16 mg/L), not nearly tripling to 32 mg/L. The disproportionate jump is the diagnostic clue against first-order. (The Zero-Order PEA Pattern)
- C: CYP induction would lower phenytoin levels, not raise them, and would take weeks of co-administration with a known inducer. Phenytoin is itself an inducer; it does not auto-induce in a way that paradoxically raises its own level.
- D: $V_d$ is a fixed pharmacokinetic property of the drug-patient pair and does not increase with plasma concentration. An increased $V_d$ would actually lower the measured concentration, the opposite of what is observed.
Which mechanism best explains the change in this patient's INR?
- A Rifampin-induced upregulation of hepatic CYP2C9 increasing warfarin metabolism ✓ Correct
- B Isoniazid-mediated inhibition of warfarin protein binding
- C Pyrazinamide displacement of warfarin from albumin binding sites
- D Vitamin K malabsorption caused by ethambutol-induced gut dysbiosis
Why A is correct: Rifampin is one of the most potent inducers of hepatic CYP450 enzymes, including CYP2C9, the primary enzyme that metabolizes the active S-enantiomer of warfarin. Induction increases warfarin clearance and lowers plasma levels, producing a fall in INR within 1–3 weeks of starting rifampin. The patient now needs a higher warfarin dose, with continued frequent monitoring while on TB therapy and again when rifampin is stopped.
Why each wrong choice fails:
- B: Isoniazid is a CYP inhibitor (would raise INR, not lower it) and does not work by displacing warfarin from protein binding. The directionality is wrong for the observed INR drop. (The CYP Inducer/Inhibitor Drug-Drug Interaction)
- C: Protein-binding displacement causes a transient rise in free drug, which would raise INR briefly before being rebalanced by increased clearance. Pyrazinamide is not a clinically significant warfarin interactor by this mechanism. (The CYP Inducer/Inhibitor Drug-Drug Interaction)
- D: Ethambutol's main toxicity is optic neuritis, not gut dysbiosis. Vitamin K malabsorption from antibiotic-induced dysbiosis would raise INR (less vitamin K → less clotting factor synthesis), not lower it.
Memory aid
"PEA sits on zero" — Phenytoin, Ethanol, Aspirin (toxic doses) follow zero-order kinetics. For inducers, "Chronic alcoholics Steal Phen-Phen and Refuse Greasy Carbs": Chronic alcohol, St. John's wort, Phenytoin, Phenobarbital, Rifampin, Griseofulvin, Carbamazepine. For inhibitors, "SICKFACES.COM": Sodium valproate, Isoniazid, Cimetidine, Ketoconazole, Fluconazole, Alcohol (acute), Chloramphenicol, Erythromycin, Sulfonamides, Ciprofloxacin, Omeprazole, Metronidazole.
Key distinction
Loading dose vs maintenance dose: loading depends only on $V_d$ and target concentration (unchanged in organ failure); maintenance depends on clearance (must be reduced in renal/hepatic failure). Mixing these up is the single most-tested PK trap.
Summary
Master three equations — $V_d = \text{dose}/C_0$, $\text{CL} = 0.7 V_d / t_{1/2}$, and the loading vs maintenance dose formulas — and you can answer almost any USMLE PK item by identifying which parameter the stem is asking about.
Practice pharmacokinetics (adme) adaptively
Reading the rule is the start. Working USMLE Step 1 & 2-format questions on this sub-topic with adaptive selection, watching your mastery score climb in real time, and seeing the items you missed return on a spaced-repetition schedule — that's where score lift actually happens. Free for seven days. No credit card required.
Start your free 7-day trialFrequently asked questions
What is pharmacokinetics (adme) on the USMLE Step 1 & 2?
Pharmacokinetics (PK) describes what the body does to a drug across four phases — Absorption, Distribution, Metabolism, Excretion. Three derived parameters do most of the USMLE work: volume of distribution ($V_d$) determines the loading dose, clearance (CL) determines the maintenance dose and steady-state concentration, and half-life ($t_{1/2}$) determines how long until steady state and how long until washout. Most stems test whether you can pick the right equation for the question being asked rather than memorize numbers.
How do I practice pharmacokinetics (adme) questions?
The fastest way to improve on pharmacokinetics (adme) is targeted, adaptive practice — working questions that focus on your specific weak spots within this sub-topic, getting immediate feedback, and revisiting items you missed on a spaced-repetition schedule. Neureto's adaptive engine does this automatically across the USMLE Step 1 & 2; start a free 7-day trial to see your sub-topic mastery climb in real time.
What's the most important distinction to remember for pharmacokinetics (adme)?
Loading dose vs maintenance dose: loading depends only on $V_d$ and target concentration (unchanged in organ failure); maintenance depends on clearance (must be reduced in renal/hepatic failure). Mixing these up is the single most-tested PK trap.
Is there a memory aid for pharmacokinetics (adme) questions?
"PEA sits on zero" — Phenytoin, Ethanol, Aspirin (toxic doses) follow zero-order kinetics. For inducers, "Chronic alcoholics Steal Phen-Phen and Refuse Greasy Carbs": Chronic alcohol, St. John's wort, Phenytoin, Phenobarbital, Rifampin, Griseofulvin, Carbamazepine. For inhibitors, "SICKFACES.COM": Sodium valproate, Isoniazid, Cimetidine, Ketoconazole, Fluconazole, Alcohol (acute), Chloramphenicol, Erythromycin, Sulfonamides, Ciprofloxacin, Omeprazole, Metronidazole.
What's a common trap on pharmacokinetics (adme) questions?
Adjusting loading dose for renal failure (you don't — only maintenance changes)
What's a common trap on pharmacokinetics (adme) questions?
Confusing zero-order vs first-order kinetics on phenytoin/ethanol/aspirin stems
Ready to drill these patterns?
Take a free USMLE Step 1 & 2 assessment — about 25 minutes and Neureto will route more pharmacokinetics (adme) questions your way until your sub-topic mastery score reflects real improvement, not luck. Free for seven days. No credit card required.
Start your free 7-day trial